Patients with chronic hepatitis B exhibiting significant inflammation and fibrosis should pay particular attention to the status of hepatic steatosis during antiviral therapy
In CHB patients with significant inflammation and fibrosis, the persistence of hepatic steatosis during antiviral treatment may impede the improvement of inflammation and fibrosis, leading to disease progression and biochemical abnormalities.
Authors
- Bingqing Yang (ORCID: https://orcid.org/0000-0001-9947-8327)
- Qi Wang
- Tianyuan Yang (ORCID: https://orcid.org/0000-0003-4219-837X)
- C. Hou (ORCID: https://orcid.org/0009-0008-4004-5613)
Institutions
- Capital Medical University (CN)
- Beijing Ditan Hospital (CN)
Publication Details
- Journal
- Virology Journal
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1186/s12985-025-02703-z
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35